CYTK · Cytokinetics Inc
Market Cap
$10.94B
Shares
139.02M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$77.90
Open$78.84
Day$77.84–79.13
52W close$35.33–87.26
Avg vol 30d1.7M
Short int16.3M · 11.7% float · 7.7d
Short vol69%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+12%
above
Price vs 50-day avg
−3%
below
RSI (14)
50
neutral
MACD trend
Positive
52-week position
82%
mid-range
Momentum
relative strength
1-month return
−3%
trailing
6-month return
+29%
trailing
YTD return
+23%
this year
Relative strength
+14%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $80 › 200d $70 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +92 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.74% of float · ▲ +6.7% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
484 holders — near 3-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
−87%
Y/Y
EPS growth
−24%
Y/Y
Free cash flow
$-534.8M
Balance sheet
$165.0M
net debt
Quant / Vol
risk profile
Volatility
60%
annualized · 1-yr
Max drawdown
−16%
past year
ATR
3.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
GAAP combined R&D and SG&A Expense
· full year 2026
GAAP
Maintained
$860M – $890M
Jun 30, 2026
$860M – $890M
changed to
Aug 6, 2026
$860M – $890M
Prior guidance
period ended
· from the 8-K filed Nov 5, 2025
GAAP operating expense
· full year 2025
$680M – $700M
Guided vs delivered
· last 1 settled
Revenue
2023
guided $5M
$7.53M
Beat +50.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+12%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
50
Neutral
MACD trend
Positive
Bullish
52-week position
82%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $80 › 200d $70 — 50d above 200d
Institutional flow
Accumulating
+7% holders QoQ · +92 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.74% of float · ▲ +6.7% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
484 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $35
Now $78 · 82%
Range high $87
vs 200-day avg +12%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| patients dispensed MYQORZO | 1,500 | As of June 30, 2026 | — |
| patients on therapy on paid prescription | 80% | As of June 30, 2026 | — |
| Restricted stock units | 1,460,603 | the first quarter of 2026 filing | — |
| Stock options | 1,518,443 | the first quarter of 2026 filing | — |
| unique healthcare providers prescribed MYQORZO | 700 | As of June 30, 2026 | — |
| cash, cash equivalents and investments | $1.1B | March 31, 2026 | — |
| HCPs REMS certified | 1,400 | Q1 2026 | — |
| patients prescribed MYQORZO | 680 | Q1 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CYTK
this stock
Cytokinetics Inc
|
$10.94B | +22.6% | -87.4% | — | 11.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +4.6% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CYTK | +0.9% | -3.1% | +29.0% | +1.0% | +22.6% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -0.2% | -7.1% | +14.3% | -2.2% | +9.5% |
Key facts
CIK
1061983
CUSIP
23282W605
13F (30d)
398 filings
397 filers
Visit website
Investor relations